Transcode Therapeutics (RNAZ) Non Operating Income (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Non Operating Income came in at $201267.0 in Q1 2026, up 102.26% YoY from $99510.1 in Q1 2025, and down 92.84% on a QoQ basis from $2.8 million in Q4 2025.
Transcode Therapeutics (RNAZ) Non Operating Income (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Non Operating Income data on file, last reported at $201267.0 in Q1 2026.
- Quarterly Non Operating Income rose 102.26% year-over-year to $201267.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 126.68% YoY) and the FY2025 annual result came in at -$6.5 million, down 489.88% from the prior year.
- Non Operating Income slipped to $201267.0 in Q1 2026, from $2.8 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $2.8 million in Q4 2025 to a low of -$8.9 million in Q1 2025.
- A 5-year average of -$318039.0 and a median of $10041.0 in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income jumped 2098.29% — and 2025, when it slumped 23463.93%.
- Tracing RNAZ's Non Operating Income over 5 years: stood at $361417.0 in 2022, then plunged by 97.22% to $10041.0 in 2023, then tumbled by 8302.07% to -$823570.0 in 2024, then soared by 441.14% to $2.8 million in 2025, then plunged by 92.84% to $201267.0 in 2026.
- The last three Non Operating Income figures came in at $201267.0 (Q1 2026), $2.8 million (Q4 2025), and -$294851.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | 39,677.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 201,267.00 |
| Dec 31, 2025 | 2.81 Mn |
| Sep 30, 2025 | -294,851.00 |
| Jun 30, 2025 | -55,368.00 |
| Mar 31, 2025 | -8.91 Mn |
| Dec 31, 2024 | -823,570.00 |
| Sep 30, 2024 | -155,975.00 |
| Jun 30, 2024 | -76,898.00 |
| Mar 31, 2024 | -37,830.00 |
| Dec 31, 2023 | 10,041.00 |
| Sep 30, 2023 | 10,290.00 |
| Jun 30, 2023 | 781,340.00 |
| Mar 31, 2023 | 70,750.00 |
| Dec 31, 2022 | 361,417.00 |
| Sep 30, 2022 | 663,950.00 |
| Jun 30, 2022 | 36,061.00 |
| Mar 31, 2022 | 7,432.00 |
| Dec 31, 2021 | 186,975.00 |
| Sep 30, 2021 | 30,203.00 |
| Jun 30, 2021 | 3.13 Mn |